Literature DB >> 20673675

Malnutrition at the time of diagnosis is associated with a shorter disease duration in ALS.

Nadège Limousin1, Hélène Blasco, Philippe Corcia, Paul H Gordon, Bertrand De Toffol, Christian Andres, Julien Praline.   

Abstract

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. During the course of the illness, malnutrition can occur and may shorten survival. The aim of our study was to determine whether clinical nutritional parameters that are used in daily practice are associated with prognosis and whether they can help guide therapeutic decisions.
METHODS: We retrospectively reviewed a cohort of ALS patients in our institution between January 2002 and January 2006. Clinical and demographic outcomes were compiled. To evaluate predictors of survival, we analyzed several clinical nutritional parameters available in daily practice (body mass index, weight loss exceeding 10% of premorbid weight at the time of diagnosis and during the course of the disease and the use of technical supports such as percutaneous endoscopic gastrostomy (PEG) and non-invasive ventilation).
RESULTS: Sixty-three patients were retrospectively studied. Thirteen patients had weight loss exceeding 10% of premorbid weight at the time of diagnosis and thirty patients had weight loss meeting this criterion at final examination. Weight loss exceeding 10% at the time of diagnosis was associated with a shorter duration of disease (17±6months versus 35±26months; p=0.002). A linear correlation was found between mean disease duration and time between onset and diagnosis (p<0.0001). The subgroup of patients with a PEG had a longer survival time than the other subgroup of patients (p=0.02).
CONCLUSIONS: In ALS patients, early and marked weight loss significantly predicts a worse prognosis. The percentage of premorbid weight loss is a suitable and useful measure that can be used in daily practice to identify patients with a poor prognosis. Crown Copyright 2010. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20673675     DOI: 10.1016/j.jns.2010.06.028

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  17 in total

Review 1.  Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials.

Authors:  Paul H Gordon
Journal:  Aging Dis       Date:  2013-10-01       Impact factor: 6.745

Review 2.  Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis.

Authors:  Carlayne E Jackson; April L McVey; Stacy Rudnicki; Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

Review 3.  Clinical diagnosis and management of amyotrophic lateral sclerosis.

Authors:  Orla Hardiman; Leonard H van den Berg; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

4.  Effects of Percutaneous Endoscopic Gastrostomy in Patients With Huntington Disease.

Authors:  Emma Frank; Allison Dyke; Sarah MacKenzie; Evagelia Maskwa; Samuel Frank
Journal:  Neurol Clin Pract       Date:  2021-12

Review 5.  Body mass index and survival from amyotrophic lateral sclerosis: A meta-analysis.

Authors:  Efthimios Dardiotis; Vasileios Siokas; Maria Sokratous; Zisis Tsouris; Athina-Maria Aloizou; Desponia Florou; Metaxia Dastamani; Alexios-Fotios A Mentis; Alexandros G Brotis
Journal:  Neurol Clin Pract       Date:  2018-10

6.  Communication Support for People with ALS.

Authors:  David Beukelman; Susan Fager; Amy Nordness
Journal:  Neurol Res Int       Date:  2011-04-14

7.  Improvement of oxidative and metabolic parameters by cellfood administration in patients affected by neurodegenerative diseases on chelation treatment.

Authors:  Alessandro Fulgenzi; Rachele De Giuseppe; Fabrizia Bamonti; Maria Elena Ferrero
Journal:  Biomed Res Int       Date:  2014-07-10       Impact factor: 3.411

8.  Prognostic Factors in Amyotrophic Lateral Sclerosis: A Population-Based Study.

Authors:  Mirian Conceicao Moura; Maria Rita Carvalho Garbi Novaes; Emanoel Junio Eduardo; Yuri S S P Zago; Ricardo Del Negro Barroso Freitas; Luiz Augusto Casulari
Journal:  PLoS One       Date:  2015-10-30       Impact factor: 3.240

9.  The interplay between metabolic homeostasis and neurodegeneration: insights into the neurometabolic nature of amyotrophic lateral sclerosis.

Authors:  S T Ngo; F J Steyn
Journal:  Cell Regen (Lond)       Date:  2015-08-27

10.  Iron metabolism disturbance in a French cohort of ALS patients.

Authors:  Charlotte Veyrat-Durebex; Philippe Corcia; Aleksandra Mucha; Simon Benzimra; Cindy Mallet; Chantal Gendrot; Caroline Moreau; David Devos; Eric Piver; Jean-Christophe Pagès; François Maillot; Christian R Andres; Patrick Vourc'h; Hélène Blasco
Journal:  Biomed Res Int       Date:  2014-07-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.